Status:
COMPLETED
Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
Lead Sponsor:
Hospital Universitário Professor Edgard Santos
Conditions:
HTLV-1
Tropical Spastic Paraparesis
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
In this study the investigators are going to evaluate the efficacy pentoxifyline in HTLV-1 patients with neurological diseases: HAM/TSP or neurogenic bladder. In some laboratory experiments the invest...
Detailed Description
The human T-lymphotropic virus type 1 (HTLV-1) infects 20 million individuals worldwide and is the causative agent of HTLV associated myelopathy/ tropical spastic paraparesis (HAM/TSP). Although only ...
Eligibility Criteria
Inclusion
- Age ≥ 18 and ≤ 80 years;
- Confirmed HTLV-1 infection with Western Blot analysis;
- HAM/TSP diagnosed patients according to the WHO
- Patients with HTLV-1 and neurogenic bladder diagnosed by clinical and urodynamic study
- Disease duration \< 5 years
Exclusion
- Neurological diseases with functional limitations.
- Co-infection with Hepatitis B or C, Syphilis, Chagas Disease or HIV
- Use of immunossupressive drugs
- Immune disease
- Pregnancy
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01472263
Start Date
September 1 2009
End Date
September 1 2012
Last Update
March 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitário Professor Edgard Santos
Salvador, Estado de Bahia, Brazil, 40110